scholarly journals Anticoagulation in COVID-19.

2021 ◽  
Vol 5 (2) ◽  
Author(s):  
Ximena Veloz Ochoa ◽  
Gustavo Ayo Chipantasig ◽  
Dixon Zambrano Palma
Keyword(s):  
Health Personnel ◽  
Low Molecular Weight Heparin ◽  
Endothelial Activation ◽  
Low Molecular Weight ◽  
Cytokine Storm ◽  
Serious Adverse Events ◽  
Heparin Induced Thrombocytopenia ◽  
Infected People ◽  
Heparin Anticoagulation ◽  
Serious Disease

In 2020 declared the COVID-19 pandemic. A new SARS-Cov-2 betacoronavirus transmitted through respiratory secretions of infected people, causing lesions in the pulmonary microvasculature, endothelial activation, massive release of pro-inflammatory substances "cytokine storm", which lead to a procoagulant state and on which it will depend the development of the serious disease. The management of coagulopathy induced by COVID-19 entails stratifying the risk of thrombosis, for which heparins are the treatment of choice, especially in hospitalized patients. Low molecular weight heparin (LMWH) is the first option since its administration implies longer times and less exposure of health personnel. Unfractionated heparin is another alternative but requires laboratory controls and is sometimes not available. Heparin-induced thrombocytopenia (HIT) and bleeding are serious adverse events secondary to the use of heparin anticoagulation.

Heparin-induced thrombocytopenia in neurologic patients treated with low-molecular-weight heparin

Neurology ◽  
2005 ◽  
Vol 64 (7) ◽  
pp. 1285-1287 ◽  
Author(s):  
C. Pohl ◽  
A. Kredteck ◽  
B. Bastians ◽  
P. Hanfland ◽  
T. Klockgether ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Low Molecular Weight ◽  
Heparin Induced Thrombocytopenia

Low molecular weight heparin-induced thrombocytopenia and thrombosis

2009 ◽  
Vol 56 (5) ◽  
pp. 329-300 ◽  
Author(s):  
F. P. J. Peters ◽  
P. A. F. M. Doevendans ◽  
F. L. G. Erdkamp ◽  
F. W. C. Ent ◽  
F. Heer
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Low Molecular Weight ◽  
Heparin Induced Thrombocytopenia

Heparin-Induced Thrombocytopenia during Obstetric Hospital Admissions

2018 ◽  
Vol 35 (09) ◽  
pp. 898-903 ◽  
Author(s):  
Deepika Sagaram ◽  
Zainab Siddiq ◽  
Andrew Eisenberger ◽  
Cande Ananth ◽  
Jason Wright ◽  
...  
Keyword(s):  
Heart Failure ◽  
Arterial Thrombosis ◽  
Low Molecular Weight Heparin ◽  
Hospital Admissions ◽  
The United States ◽  
Limb Amputation ◽  
Administrative Database ◽  
Low Molecular Weight ◽  
Heparin Induced Thrombocytopenia ◽  
Pharmacologic Prophylaxis

Introduction The rate of heparin-induced thrombocytopenia (HIT) on a population basis is unknown. The objective of this study was to characterize the risk for HIT during antepartum, delivery, and postpartum hospitalizations in the United States. Materials and Methods A large administrative database was used to determine the risk of HIT in hospitalized obstetric patients who received unfractionated heparin (UFH) or low molecular weight heparin (LMWH). Patients were presumed to have HIT if they were exposed to UFH or LMWH, received a diagnosis of HIT, and were administered a medication for the treatment of HIT including bivalirudin, argatroban, fondaparinux, or lepirudin. We queried severe complications of HIT including arterial thrombosis, limb amputation, heart failure, and death. Results We identified 66,468 antepartum hospitalizations, 66,741 delivery hospitalizations, and 16,325 postpartum readmissions where women received pharmacologic prophylaxis. Of these, 10 antepartum admissions, 1 delivery admission, and 14 postpartum readmissions involved a diagnosis of HIT with treatment of bivalirudin, argatroban, fondaparinux, or lepirudin. There were no deaths and no diagnoses of arterial thrombosis, limb amputation, heart failure, and death. Conclusion Risk for HIT among hospitalized obstetric patients is low. In this cohort, no cases of death or severe complications were noted in relation to the diagnosis.

The incidence of heparin-induced thrombocytopenia in patients treated with low molecular weight heparin for superficial vein thrombosis

2016 ◽  
Vol 139 ◽  
pp. 154-157 ◽  
Author(s):  
Michelangelo Sartori ◽  
Elisabetta Favaretto ◽  
Ludovica Migliaccio ◽  
Giuliana Guazzaloca ◽  
Cristina Legnani ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Low Molecular Weight ◽  
Superficial Vein ◽  
Heparin Induced Thrombocytopenia ◽  
Vein Thrombosis ◽  
Superficial Vein Thrombosis

scholarly journals Reversal of Low-Molecular-Weight Heparin Anticoagulation by Synthetic Protamine Analogues

1994 ◽  
Vol 56 (6) ◽  
pp. 586-593 ◽  
Author(s):  
Thomas W. Wakefield ◽  
Philip C. Andrews ◽  
Shirley K. Wrobleski ◽  
Amy M. Kadell ◽  
Antonio Fazzalari ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Low Molecular Weight ◽  
Heparin Anticoagulation

scholarly journals Risk factors governing the development of cerebral vein and dural sinus thrombosis after craniotomy in patients with intracranial tumors

2018 ◽  
Vol 128 (2) ◽  
pp. 373-379 ◽  
Author(s):  
Florian Gessler ◽  
Markus Bruder ◽  
Stephan Duetzmann ◽  
Stephanie Tritt ◽  
Joshua D. Bernstock ◽  
...  
Keyword(s):  
Risk Factors ◽  
Low Molecular Weight Heparin ◽  
Sinus Thrombosis ◽  
Dural Sinus ◽  
Low Molecular Weight ◽  
Cerebral Vein ◽  
Modified Rankin Scale ◽  
Tumor Removal ◽  
Heparin Anticoagulation ◽  
Intermediate Dose

OBJECTIVENeurosurgical intervention may increase the risk of developing cerebral vein and dural sinus thrombosis (CVT). The clinical management of CVT in postoperative patients remains unclear. This retrospective study explores the disease occurrence, associated risk factors, and outcomes in patients with tumors who developed CVT after craniotomy.METHODSA retrospective analysis and review of patient records in those who had undergone cranial tumor removal within the authors' neurosurgical department was performed. In so doing, the authors identified a cohort of patients who developed CVT postoperatively. The study included patients who presented to the department between January 2004 and December 2013.RESULTSOf 2286 patients with intracranial lesions who underwent craniotomy, 35 (1.5%) went on to develop CVT. The authors identified the semisitting position (OR 7.55, 95% CI 3.73–15.31, p < 0.001); intraoperative sinus injury (OR 1.5, 95% CI 3.57–15.76, p < 0.001); and known CVT risk factors (OR 7.77, 95% CI 2.28–21.39, p < 0.001) as predictors of CVT development. Of note, 19 patients (54.3%) had good outcomes (modified Rankin Scale Score 0–1), whereas 9 patients (25.7%) had suffered dependency or death (modified Rankin Scale Score 4–6) at last follow-up. Intracerebral hemorrhage (OR 21.27, 95% CI 1.59–285.01, p = 0.02) and delayed delivery of an intermediate dose of low-molecular-weight heparin anticoagulation (OR 24.12, 95% CI 2.08–280.13, p = 0.01) were associated with unfavorable outcomes.CONCLUSIONSOnly a minority of patients undergoing craniotomy for tumor removal develop CVT, and the majority of those who do develop CVT recover well. Early administration of an intermediate dose of low-molecular-weight heparin anticoagulation might be considered once CVT is diagnosed.

Sign in / Sign up

Export Citation Format

Share Document